Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Upcoming Events and Highlights
Investor News
Share Price / Index
September 10, 2024
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer issues 750 million euro hybrid bond
September 10, 2024
Not intended for UK Media – Late-breaking data from Phase III long-term study OASIS 3 presented at 2024 TMS Annual Meeting:
Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause
September 10, 2024
Not intended for U.S. and UK Media – Late-breaking data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024
New subgroup analysis from FINEARTS-HF revealed patients with heart failure and a left ventricular ejection fraction of ≥40% receiving finerenone had a reduced risk of new-onset diabetes
Discover More
